Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given a consensus recommendation of “Hold” by the nine ratings firms that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $8.24.

A number of equities analysts have recently commented on ZNTL shares. UBS Group cut their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th.

Insider Transactions at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Scott Dunseth Myers purchased 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the director now owns 281,192 shares of the company’s stock, valued at $393,668.80. The trade was a 8.07 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Almitas Capital LLC increased its position in shares of Zentalis Pharmaceuticals by 69.3% during the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock valued at $4,929,000 after purchasing an additional 665,968 shares during the last quarter. Primecap Management Co. CA lifted its stake in Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock valued at $4,608,000 after purchasing an additional 22,600 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zentalis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company’s stock valued at $3,979,000 after purchasing an additional 20,864 shares during the period. D. E. Shaw & Co. Inc. increased its position in Zentalis Pharmaceuticals by 9.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock worth $3,756,000 after buying an additional 110,882 shares during the last quarter. Finally, Integral Health Asset Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $3,182,000.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.45 on Monday. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $13.24. The stock’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $2.45. The firm has a market capitalization of $104.13 million, a P/E ratio of -0.58 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter. As a group, equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.